Table 2.
Relationship between various parameters at 10-year post-liver transplantation and the incidence of hepatic steatosis on 10-year post-liver transplantation biopsy
| All subjects n = 72 | No HS n = 48 | HS n = 24 | P1 | |
| Age at the time of survey | 49 ± 15 | 47 ± 15 | 53 ± 12 | NS |
| ≥ 60 yr aged patients | 28% | 27% | 29% | NS |
| Histological lesions | ||||
| Steatosis | 33% | - | 100% | |
| Macrovacuolar | 28% | - | 82% | |
| Microvacuolar | 1% | - | 4% | |
| Combined Mac-Mic | 4% | - | 14% | |
| Initial and 10-yr maintained steatosis | 8% (5 pat.) | 0% | 22% | 0.002 |
| Fibrosis (F1-F4) | 53% | 44% | 71% | 0.03 |
| F1-F2 | 40% | 35% | 50% | NS |
| F3-F4 | 13% | 8% | 21% | NS |
| Combined fibrosis-steatosis | 24% | 0% | 71% | < 0.0001 |
| HCV(+) Fibrosis | 44% | 31% | 71% | < 0.001 |
| Bile duct lesions | 36% | 42% | 25% | NS |
| Minimal change | 23% | 27% | 17% | NS |
| Other potential steatosis factors | ||||
| BMI (kg/m2) | 22.4 ± 3.8 | 22.3 ± 3.9 | 22.6 ± 3.4 | NS |
| Underweight (BMI ≤ 18.5) | 13% | 17% | 4% | |
| Normal weight (BMI = 18.5-24.9) | 69% | 65% | 79% | NS |
| Overweight (BMI = 25-29.9) | 14% | 14% | 13% | |
| Obesity (BMI ≥ 30) | 4% | 4% | 4% | |
| HCV infection (de novo or recurrence) | 57% | 46% | 79% | 0.007 |
| Arterial hypertension | 53% | 52% | 54% | NS |
| Glycemia (mmol/L) | 5.4 ± 2.0 | 5.1 ± 0.9 | 6.2 ± 3.2 | NS |
| Diabeties mellitus | 10% | 8% | 13% | NS |
| Maintenance immunosuppresssion | ||||
| Cyclosporine A | 96% | 96% | 96% | NS |
| Dosage (mg) | 129.8 ± 58.1 | 135.0 ± 61.5 | 119.5 ± 50.4 | NS |
| Prednisolone | 93% | 96% | 88% | NS |
| Dosage (mg) | 6.8 ± 3.1 | 6.9 ± 3.2 | 6.7 ± 2.9 | NS |
| Azathioprine | 43% | 40% | 50% | NS |
| Dosage (mg) | 48.4 ± 15.7 | 51.3 ± 15.5 | 43.8 ± 15.5 | NS |
Continuous data are represented as mean ± SD, and categorical data as percentage.
1
Comparison between HS and No HS. HS: Hepatic steatosis; NS: Not significant; BMI: Body mass index.